Skip to content

US · SCYX · MEDICAL - PHARMACEUTICALS

SCYNEXIS, Inc. (SCYX) intrinsic value and stock valuation

$2.38as of 2026-11-21 · Mkt cap 32.45M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

SCYNEXIS, Inc. DCF and intrinsic value

InvestorsCraft values SCYX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from SCYX’s statements →

SCYNEXIS, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Pharmaceuticals Jersey City, NJ 07302-6548 scynexis.com

How the business is doing

Fiscal 2012–2025, USD

Revenue
$20.6M
20122025
Net income
-$-8.61M
20122025
Free cash flow
-$-5.28M
20122025
Total equity
$49.4M+16.8% 5y CAGRd
20122025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2012–2025, USD
20252024202320222021
Revenue$20.6M$3.75M$140.1M$5.09M$13.2M
Operating income-$-16.07M-$-37.12M$72.7M-$-85.76M-$-60.84M
Net income-$-8.61M-$-21.29M$67M-$-62.81M-$-32.87M
EPSd-$-1.38M-$-3.51M$11.1M-$-11.78M-$-9.96M
Operating cash flow-$-5.28M-$-24.01M$60.2M-$-79.88M-$-54.56M
Capital expenditure$0.00$0.00$0.00-$-10K-$-1.17M
Free cash flow-$-5.28M-$-24.01M$60.2M-$-79.89M-$-55.73M
Total assets$59M$90.6M$128.4M$87.8M$119.8M
Total debt$2.17M$16.3M$15.1M$48.6M$43.6M
Net debt-$-19.08M$220K-$-18.97M$2.78M-$-60.86M
Total equity$49.4M$55.1M$73M$3.23M$41.3M
Cash and short-term investments$21.3M$59.3M$74.4M$73.5M$104.5M
Income statement
20252024202320222021
Revenue$20.6M$3.75M$140.1M$5.09M$13.2M
Cost of revenue$0.00$0.00$15.6M$630K$310K
Gross profit$20.6M$3.75M$124.5M$4.46M$12.9M
Research and development expenses$22.3M$26.4M$30.9M$27.3M$23.8M
Selling, general and administrative expenses$14.4M$14.5M$20.9M$63M$49.9M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$36.7M$40.9M$51.9M$90.2M$73.7M
Cost and expenses$36.7M$40.9M$67.5M$90.9M$74M
Interest income$2.18M$4.29M$3.95M$1.42M$20K
Interest expense$170K$2.55M$6.12M$6.79M$3.96M
Depreciation and amortization$310K$1.73M$580K$810K$380K
Ebitda-$-8.12M-$-18.58M$70.9M-$-59.91M-$-32.91M
Operating income-$-16.07M-$-37.12M$72.7M-$-85.76M-$-60.84M
Total other income/expenses, net$7.46M$16M-$-5.49M$18.3M$24.9M
Income before tax-$-8.61M-$-21.14M$67.2M-$-67.51M-$-35.95M
Income tax expense$0.00$150K$140K-$-4.7M-$-3.09M
Net income-$-8.61M-$-21.29M$67M-$-62.81M-$-32.87M
Weighted average shares outstanding$6.24M$6.06M$5.98M$5.33M$3.3M
Weighted average diluted shares outstanding$6.24M$6.06M$6.05M$5.33M$3.3M
Balance sheet
20252024202320222021
Cash and short-term investments$21.3M$59.3M$74.4M$73.5M$104.5M
Net receivables$0.00$10.3M$21.8M$2.1M$860K
Inventory$0.00$0.00$0.00$900K$460K
Total current assets$40.4M$72.2M$102.1M$79.1M$109.4M
Property, plant and equipment, net$1.76M$2.09M$2.36M$2.59M$2.91M
Goodwill and intangible assets$0.00$0.00$0.00$410K$1.06M
Long-term investments$16.3M$15.9M$23.6M$160K$220K
Total non-current assets$18.7M$18.5M$26.3M$8.75M$10.5M
Total assets$59M$90.6M$128.4M$87.8M$119.8M
Accounts payable$2.23M$4.57M$7.15M$5.94M$7.85M
Short-term debt$480K$14.1M$340K$280K$140K
Deferred revenue$230K$1.64M$1.19M$0.00$0.00
Total current liabilities$5.73M$24.1M$16.3M$17.6M$13.6M
Long-term debt$1.69M$2.17M$14.7M$48.3M$43.6M
Deferred revenue, non-current$0.00$1.29M$2.73M$0.00$0.00
Total non-current liabilities$3.92M$11.5M$39.2M$67M$65M
Capital lease obligations$2.17M$2.58M$2.92M$3.2M$3.27M
Total liabilities$9.65M$35.6M$55.5M$84.6M$78.6M
Common stock$50K$40K$40K$40K$30K
Retained earnings-$-385.14M-$-376.54M-$-355.25M-$-422.29M-$-359.48M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$49.4M$55.1M$73M$3.23M$41.3M
Total investments$16.3M$59.1M$63.9M$27.9M$220K
Total debt$2.17M$16.3M$15.1M$48.6M$43.6M
Net debt-$-19.08M$220K-$-18.97M$2.78M-$-60.86M
Cash flow statement
20252024202320222021
Net income-$-8.61M-$-21.29M$67M-$-62.81M-$-32.87M
Depreciation and amortization$310K$1.73M$580K$610K$380K
Stock-based compensation$2.85M$3.35M$2.62M$3.69M$2.09M
Change in working capital$6.08M$7.28M-$-30.64M$760K$3.15M
Accounts receivable$10.3M$11.6M-$-19.73M-$-1.24M-$-860K
Inventory$0.00$0.00-$-8.85M-$-440K-$-5.29M
Accounts payable-$-2.23M-$-2.65M$1.17M-$-1.48M$2.76M
Net cash provided by operating activities-$-5.28M-$-24.01M$60.2M-$-79.88M-$-54.56M
Investments in property, plant and equipment$0.00$0.00$0.00-$-10K-$-1.17M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$24.3M$6.15M-$-34.88M-$-27.39M-$-1.17M
Common stock issued-$-170K-$-140K$20K$47.3M$38.6M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-14.17M-$-140K-$-36.72M$48.6M$67.1M
Net change in cash$4.85M-$-18M-$-11.44M-$-58.67M$11.4M
Cash at end of period$21.5M$16.6M$34.6M$46M$104.7M
Operating cash flow-$-5.28M-$-24.01M$60.2M-$-79.88M-$-54.56M
Capital expenditure$0.00$0.00$0.00-$-10K-$-1.17M
Free cash flow-$-5.28M-$-24.01M$60.2M-$-79.89M-$-55.73M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About SCYNEXIS, Inc.

        SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.

        CEO
        David Angulo
        Employees
        18
        Beta
        1.10

        Explore

        Frequently asked questions

        What is the intrinsic value of SCYNEXIS, Inc. (SCYX)?

        InvestorsCraft does not currently publish an intrinsic value for SCYX. How the IC value is calculated.

        Is SCYX undervalued?

        InvestorsCraft does not publish an undervaluation signal for SCYX at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.